| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-05-09 | brodalumab (AMG 827) | psoriasis |
3 | Amgen (USA) AstraZeneca (UK) | Autoimmune diseases - Dermatological diseases |
| 2014-05-09 | DAV132 | Clostridium difficile infections |
1 | Da Volterra (France) | Infectious diseases |
| 2014-05-09 | Vibativ® (telavancin) | complicated skin and skin structure infections (cSSSI) including methicillin-resistant Staphylococcus aureus (MRSA) |
3 | Theravance (USA) | Infectious diseases |
| 2014-05-09 | ceftolozane/tazobactam | complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) |
3 | Cubist Pharmaceuticals (USA - MA) | Infectious diseases |
| 2014-05-09 | GS-6615 | long QT-3 (LQT3) syndrome |
1 | Gilead (USA) | Cardiovascular diseases - Genetic diseases |
| 2014-05-08 | Letermovir (AIC246) | prevention of HCMV (human cytomegalovirus) disease
|
2 | Aicuris (Germany) Merck&Co (USA) | Infectious diseases |
| 2014-05-08 | ETS2101 (dexanabinol) | primary or secondary brain cancer |
1 | e-Therapeutics (UK) | Cancer - Oncology |
| 2014-05-08 | ConfirmMDx® for Prostate Cancer | prostate cancer |
MDX Health (Belgium) | Cancer - Oncology | |
| 2014-05-07 | autologous bone marrow-derived CD133+ cells | ischemic refractory cardiomyopathy |
1 | Centro Cardiologico Monzino (Italy) BioCardia (USA - CA) | Cardiovascular diseases |
| 2014-05-06 | ALX-0171 | Respiratory Syncytial Virus (RSV) infections |
1 | Ablynx (Belgium) | Respiratory diseases - Infectious diseases |
| 2014-05-06 | ATX-F8-117 | factor VIII intolerance | preclinical | Apitope International (UK-Belgium) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2014-05-05 | delafloxacin | acute bacterial skin and skin structure infections (ABSSSI) | 3 | Melinta Therapeutics (USA - CT) | Infectious diseases |
| 2014-05-05 | COVA322 | psoriasis |
1b-2a | Covagen (Switzerland) | Autoimmune diseases - Dermatological diseases |
| 2014-05-05 | Signifor® LAR (pasireotide long-acting release; SOM230) | acromegaly |
3 | Novartis (Switzerland) | Hormonal diseases - Rare diseases - Endocrine diseases |
| 2014-05-05 | ReS39 | type 2 diabetes mellitus |
preclinical | reMYND (Belgium) | Metabolic diseases |
| 2014-05-02 | CA4P (fosbretabulin tromethamine) | PNET or GI-NET neuroendocrine tumors | 2 | Mateon Therapeutics (USA - CA) | Cancer - Oncology |
| 2014-05-02 | volanesorsen (ISIS-APOCIIIRx) | patients with high triglycerides and type 2 diabetes |
2 | Isis Pharmaceuticals (USA - CA) | Cardiovascular diseases - Metabolic diseases |
| 2014-05-02 | ConfirmMDx® for Prostate Cancer | prostate cancer |
MDX Health (Belgium) | Cancer - Oncology | |
| 2014-05-01 | LGH447/PIM447 and BYL719 | relapsed and refractory multiple myeloma | 1-2 | Novartis (Switzerland) | Cancer - Oncology |
| 2014-05-01 | VX-661 ( tezacaftor) and Kalydeco® (ivacaftor) | cystic fibrosis |
2 | Vertex Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
